ALT: מחיר לרווח מתואם קצב צמיחה altimmune.com
The historical PEG ratio reflects the impact of partnership expectations for the final tests of the obesity drug. Altimmune, Inc. (ALT) develops advanced peptide therapies to combat metabolic disorders, leveraging US laboratories and inhalation technologies. The value of 0.00 serves as a current metric that allows for the comparison of the company's market value with its earnings growth rate.
פילוחי מדדים ואנליטיקה של חברת Altimmune, Inc. (ALT)
This metric correlates market capitalization with earnings growth rates, allowing for the identification of an undervalued asset when the value falls below one. By analyzing the average peg_co level, an investor assesses the growth potential of Altimmune, Inc. (ALT) as its anti-obesity drug prepares for large-scale testing and the company seeks a strategic pharmaceutical partner to execute late-stage research.
